Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2018

View Archived Issues

VEGF-D found as a potential new biomarker of heart failure

HE-4 is a novel prognostic marker for dilated cardiomyopathy

Sanofi Genzyme declines opt-in on development and commercialization of lumasiran

Sarepta plans rolling NDA submission to seek accelerated approval of golodirsen for DMD

SNA-125 begins proof-of-concept trial in atopic dermatitis

MIDD-0301 described as a novel GABA(A) receptor ligand with clinical potential for asthma

Ritter announces microbiome data from phase IIb study of RP-G28

CAD-1883 begins phase I trial for SCA and essential tremor

EMA validates MAA for Xyndari for sickle cell disease

Phase II data presented for JVS-100 in patients with critical limb ischemia

Phase III RESULT study of Sollpura does not meet primary endpoint

Athersys and Healios plan expansion of MultiStem collaboration

FDA grants breakthrough therapy designation for CFTR amplifier PTI-428

Altimmune reports preclinical data comparing SparVax-L and BioThrax against anthrax infection

Biogen to acquire PF-04958242 from Pfizer

YIR-821 shows promise for HIV infection

FDA places clinical hold on phase I/II study of axalimogene filolisbac with durvalumab

UCL studies FLT180a gene therapy in patients with hemophilia B

Purdue Research Foundation patents FLT3 inhibitors

Curadim initiates phase I trials of CP-1050 in U.K.

Neuro-Bio divulges novel nicotinic receptor modulators

Aldeyra Therapeutics identifies aldehyde-trapping compounds

Merck & Co. discovers FXIa and plasma kallikrein inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...